Reimbursement decisions in health policy - Extending our understanding of the elements of decision-making

Health Policy

Volumn 73, Issue 3, 2005, Pages 330-338

  Wirtz, Veronika ^a,b   Cribb, Alan ^c   Barber, Nick ^a  

^a UNIVERSITY OF LONDON   (United Kingdom)

^b INSTITUTO NACIONAL DE SALUD PÚBLICA   (Mexico)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Health policy; National Health Service; Reimbursement; Rivastigmine; Sildenafil; Statins; United Kingdom

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; RIVASTIGMINE; SILDENAFIL;

ARTICLE; COST EFFECTIVENESS ANALYSIS; HEALTH CARE POLICY; HEALTH SERVICE; MEDICAL DECISION MAKING; NATIONAL HEALTH SERVICE; PATIENT CARE; REIMBURSEMENT; SOCIAL ASPECT;

HEALTH CARE AND PUBLIC HEALTH;

DECISION MAKING, ORGANIZATIONAL; DRUG COSTS; GREAT BRITAIN; HEALTH POLICY; REIMBURSEMENT MECHANISMS; STATE MEDICINE;

EID: 22544465549     PISSN: 01688510     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healthpol.2004.12.002     Document Type: Article

References (22)

1. D.K. Martin, J.L. Pater, and P.A. Singer Priority-setting decisions for new cancer drugs: a qualitative case study Lancet 358 2001 1676 1681
2. R. Foy, J. So, E. Rous, and H. Scarffe Perspectives of commissioners and cancers specialists in prioritizing new cancer drugs: impact of the evidence threshold British Medical Journal 318 1999 456 459
3. R. McDonald, P. Burrill, and T. Walley Managing the entry of new medicines in the National Health Service: health authority experience and prospects for primary care groups and trusts Health and Social Care in the Community 9 2001 341 347
4. A. Maynard Rationing health care: an exploration Health Policy 49 1999 5 11
5. T. Hope, N. Hicks, D.J.M. Reynolds, R. Crisp, and S. Griffiths Rationing and the health authority British Medical Journal 317 1998 1067 1069
6. V. Wirtz, A. Cribb, and N. Barber Understanding the role of "the hidden curriculum" in resource allocation - the case of the UK NHS Health Care Analysis 11 2003 300 306
7. L. Vuorenkoski, H. Toiviainen, and E. Hemminki Drug reimbursement in Finland - a case of explicit prioritising in special categories Health Policy 66 2003 169 177
8. T.D. Rucker, and G. Schiff Drug formularies: myths-in-formation Medical Care 28 1990 928 942
9. R. Quintiliani, G.C. Grousse, and M.S. Chow P&T committee perspectives: achieving rational therapeutics through consensus-based protocols and follow-up Hospital Formulary 25 1990 283 294
10. D. Dranove, F.X. Hugdes, and M. Shanley Determinants of HMO formulary adoption decisions Health Service Research 38 2003 169 189
11. K.N. Jenkings, and N. Barber What constitutes evidence in hospital new drug decision-making? Social Science and Medicine 58 2004 1757 1766
12. Department of Health. Health service circular 1999/065. Clinical governance: quality in the new NHS. London: HMSO; 1999.
13. M. Ashworth, S. Golding, L. Shephard, and A. Majeed Prescribing incentive schemes in two NHS regions: cross sectional survey British Medical Journal 324 2002 1187 1188
14. Z. Kmietowicz Government insists NHS pays for drugs approved by NICE British Medical Journal 323 2001 1386
15. F. Khan Using medicines wisely. The place of the formulary in medicines management Hospital Pharmacist 9 2002 159 163
16. National Health Service (general medical services contracts) (prescription of drugs) regulations. London: HMSO; 2004.
17. Prescription pricing authority. Electronic drug tariff. Prescription pricing authority, 2004. Accessed on October 2004, http://www.ppa.org.uk/ppa/ edt_intro.htm.
18. Association of British Pharmaceutical Industry (ABPI). Pharma, facts and figures. How the pharmaceutical industry contributes to the health and wealth of the nation. London: ABPI; 2001.
19. D.J. Hunter Rationing: the case for muddling through elegantly British Medical Journal 311 1995 811
20. S. Toulmin Return to reason 2001 Harvard University Press Cambridge, MA
21. N. Daniels, and J. Sabin Ethics of accountability in managed care reform Health Affairs 17 1998 50 64
22. B. New The rationing agenda in the NHS British Medical Journal 312 1997 1593 1601